Biomarkers and Surrogate Endpoints in Drug Development Technical and Regulatory Considerations Biomarkers and Surrogate Endpoints in Drug Development Technical.
Surrogate Endpoints: A Regulatory View Greg Campbell, Ph.D. Director, Division of Biostatistics Center for Devices and Radiological Health Food and Drug.
1 Goals of a Lotronex ® Risk Management Program Toni Piazza-Hepp, Pharm.D. Deputy Director Division of Surveillance, Research and Communication Support.
Midterm results - Grades B to A+, mostly low A ethical theories14 rising health care costs7 23andme tests13 how are snps assayed4 GWAS6 critical eval of.
Pain Program Overview
Ucm358301
Hepatitis C Drugs - Evidence to Demonstrate Effectiveness & Value
The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind
Cross Border Corporate and Individual Tax Planning
Arzerra from approval to post marketing surveillance
Vaccine Truth
Melanoma frontline approach
